155 related articles for article (PubMed ID: 30527657)
1. Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.
Levy EB; Peer C; Sissung TM; Venkatesan A; Pandalai P; Greten T; Hughes MS; Garcia C; Peretti J; Figg W; Lewis A; Wood B
J Vasc Interv Radiol; 2019 Jan; 30(1):19-22. PubMed ID: 30527657
[TBL] [Abstract][Full Text] [Related]
2. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
Cruz JE; Saksena R; Jabbour SK; Nosher JL; Hermes-DeSantis E; Moss RA
Ann Pharmacother; 2014 Dec; 48(12):1646-50. PubMed ID: 25202035
[TBL] [Abstract][Full Text] [Related]
3. Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study.
Boeken T; Moussa N; Pernot S; Abed A; Dean C; Taieb J; Sapoval M; Pellerin O
Cardiovasc Intervent Radiol; 2020 Jun; 43(6):866-874. PubMed ID: 32103303
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Chemoembolisation of Colorectal Liver Metastases with Irinotecan-Loaded Beads: A Bi-institutional Analysis of 125 Treatments in 53 Patients.
Ngo A; von Stempel C; Corbo B; Bandula S; Shiu KK; Raja J; Hague J; Evans J; Kibrya N
Cardiovasc Intervent Radiol; 2019 Jul; 42(7):979-990. PubMed ID: 31044294
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-Eluting 75-150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study.
Fereydooni A; Letzen B; Ghani MA; Miszczuk MA; Huber S; Chapiro J; Schlachter T; Geschwind JF; Georgiades C
J Vasc Interv Radiol; 2018 Dec; 29(12):1646-1653.e5. PubMed ID: 30337148
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
Pernot S; Pellerin O; Artru P; Montérymard C; Smith D; Raoul JL; De La Fouchardière C; Dahan L; Guimbaud R; Sefrioui D; Jouve JL; Lepage C; Tougeron D; Taieb J;
Br J Cancer; 2020 Aug; 123(4):518-524. PubMed ID: 32507854
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
[TBL] [Abstract][Full Text] [Related]
8. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38.
Iwase M; Fujita KI; Nishimura Y; Seba N; Masuo Y; Ishida H; Kato Y; Kiuchi Y
Cancer Chemother Pharmacol; 2019 May; 83(5):993-998. PubMed ID: 30810774
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.
Bhutiani N; Akinwande O; Martin RC
World J Surg; 2016 May; 40(5):1178-90. PubMed ID: 26711640
[TBL] [Abstract][Full Text] [Related]
11. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1
Qin Y; Wang N; Chen F; Han X; Zhu Y; Rang Y; Zhai X; Lu Y
Pharmazie; 2020 May; 75(5):186-190. PubMed ID: 32393425
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and Safety of CT-Guided High-Dose-Rate Brachytherapy Combined with Transarterial Chemoembolization Using Irinotecan-Loaded Microspheres for the Treatment of Large, Unresectable Colorectal Liver Metastases.
Collettini F; Jonczyk M; Meddeb A; Wieners G; Geisel D; Schnapauff D; Gebauer B
J Vasc Interv Radiol; 2020 Feb; 31(2):315-322. PubMed ID: 31537409
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Liu Z; Martin JH; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell I; Crowley S; Beale PJ; Karapetis CS; Price T; Burge ME; Michael M
Eur J Clin Pharmacol; 2022 Jan; 78(1):53-64. PubMed ID: 34480602
[TBL] [Abstract][Full Text] [Related]
14. A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver.
Melancon MP; Yevich S; Avritscher R; Swigost A; Lu L; Tian L; Damasco JA; Dixon K; Cortes AC; Munoz NM; Liang D; Liu D; Tam AL
Drug Deliv; 2021 Dec; 28(1):240-251. PubMed ID: 33501859
[TBL] [Abstract][Full Text] [Related]
15. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.
Richardson AJ; Laurence JM; Lam VW
J Vasc Interv Radiol; 2013 Aug; 24(8):1209-17. PubMed ID: 23885916
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry.
Martin RC; Howard J; Tomalty D; Robbins K; Padr R; Bosnjakovic PM; Tatum C
Cardiovasc Intervent Radiol; 2010 Oct; 33(5):960-6. PubMed ID: 20661569
[TBL] [Abstract][Full Text] [Related]
18. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Riera P; Salazar J; Virgili AC; Tobeña M; Sebio A; Gallano P; Barnadas A; Páez D
Br J Clin Pharmacol; 2018 Jun; 84(6):1389-1392. PubMed ID: 29504153
[TBL] [Abstract][Full Text] [Related]
19. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.
Carling U; Dorenberg EJ; Haugvik SP; Eide NA; Berntzen DT; Edwin B; Dueland S; Røsok B
Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1532-41. PubMed ID: 25832764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
